Search Results

< Back to the upcoming events page https://www.youtube.com/watch?v=oSqUgq6QdnM Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Our 2025 NCF Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET or neuroendocrine tumor) patients and caregivers to deepen your understanding of NETs. 2025 Neuroendocrine Cancer Foundation's Annual Patient Conference Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing 11:48 Play Video 1. Welcome & Introductions • Neuroendocrine Cancer Foundation Team Now Playing 16:21 Play Video 2. What is Neuroendocrine Cancer? • Bhavana Konda, MD, MPH • Neuroendocrine Cancer Foundation Now Playing 17:33 Play Video 3. What Matters About Biomarkers & Blood Tests • Thorvardur Halfdanarson, MD • @NCFCancer Agenda Sponsors Speaker Bios Spanish Resources Watch the 2024 Conference Watch the 2023 Conference ABOUT THE CONFERENCE Our 2025 virtual annual patient conference is designed for neuroendocrine cancer (NET or neuroendocrine tumor) patients and caregivers to help you identify aspects and factors that matter most about managing your disease. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to watch this virtual conference. Learn from top neuroendocrine cancer experts from across North America, honing in on what matters-- from blood tests to clinical trials. Our experts cover the basics of Neuroendocrine Cancer, imaging, symptom management, surgery, PRRT and systemic treatments. Our speakers focus on what you need to know about that topic to help you understand your disease and next treatment options. Gain insight on what matters most in determining recommendations from expert panel discussions. Hear NET journeys from those living with Neuroendocrine Cancer. Q&A at the end of the conference presentations. Watching virtually allows you to pause, rewind and replay. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> Agenda AGENDA SPANISH RESOURCES Spanish ¿Qué importa sobre: las terapias dirigidas al hígado? Dr. Alejandro Gabutti 2025 NCF Conference Lo Importante de PRRT: ¿Qué es PRRT y Cómo Funciona? Cecilia Carreras Velázquez, MD Medicina Nuclear Hospital Ángeles Lomas 2025 NCF Conference Click here for more Spanish resources >>> THANKS TO OUR SUPPORTERS Sponsors Visit Crinetics Booth Visit Lantheus Booth Visit Exelixis Booth Visit Curium Booth The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of the Neuroendocrine Cancer Foundation.

In an effort to raise awareness about neuroendocrine cancer (NETs) in the healthcare community, we invite you to use YOUR voice, take the pledge, and join the #AskMeABoutNETs Challenge. The #AskMeAboutNETs Challenge In an effort to raise awareness about neuroendocrine cancer (NETs) in the healthcare community, we invite you to use YOUR voice, take the pledge, and join the #AskMeABoutNETs Challenge. What is the #AskMeABoutNETs Challenge? LACNETS is inspiring NET patients and allies around the world to educate their local healthcare professionals about NETs. Ready for your challenge?! We ask you to take the pledge to educate two or more of your local healthcare professionals using our #AskMeAboutNETs downloadable packets (included below). To complete the challenge, you must follow these four simple steps: Step 1: Take the pledge by clicking “take the pledge” button below. Step 2: Download the #AskMeAboutNETs information packet (included below). Step 3: Personally deliver, mail, or email the #AskMeAboutNETs information packet to at least TWO of your local health professionals. Step 4: Complete the “challenge completion form” at the bottom of this page to confirm you have completed steps 1 and 2. TAKE THE PLEDGE First Name Last Name Email TAKE THE PLEDGE Thanks for taking the pledge! Why is this challenge important? One of the biggest and most urgent challenges for the NET community is the lack of information throughout our local healthcare systems. It’s vital that we do our part to educate our local healthcare communities which can lead to earlier diagnosis and expanded research. The more of us who take the pledge, the more healthcare professionals will be reached. Our voices are stronger together! What’s in the #AskMeAboutNETS packet? To make your outreach easier, we put together downloadable packets for both patients and allies, which include: An introductory letter (from a NET patient or NET ally ) Facts about NET Symptoms of NET Resources for patients and caregivers Resources for healthcare professionals Information about NET Cancer Day (a day dedicated to increasing awareness of NET) (If you have any issues downloading the packet, please contact events@LACNETS.org.) #AskMeAboutNETs Downloadable Packets Download this packet if you are a NET patient. DOWNLOAD THE PATIENT PACKET Download this packet if you are an ally to a NET patient. DOWNLOAD THE ALLY PACKET CHALLENGE COMPLETION FORM Please complete this form after you have shared the #AskMeAboutNETs with two healthcare professionals. #AskMeAboutNETs Completion Form First Name Last Name Email Health Care Professional #1 - Please share name, title/type of health care professional, institution or clinic Health Care Professional #2 - Please share name, title/type of health care professional, institution or clinic SUBMIT Thanks for submitting!

A Study of ZL-1310 in Participants With Selected Solid Tumors << Back A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT06885281 DRUG/TREATMENT : ZL-1310 PHASE : 1/2 STATUS : Recruiting SPONSOR : Zai Lab (Shanghai) Co., Ltd. https://www.youtube.com/watch?v=RQF3krrFx_g ZL-1310 in Participants With Selected Solid Tumors .pdf Download PDF • 1.98MB DESCRIPTION: This is an open-label, multi-center Phase Ib/II study testing a new targeted treatment called ZL-1310 in selected solid tumors, including gastrointestinal and pancreatic poorly differentiated neuroendocrine carcinomas (GEP NECs) and other high-grade neuroendocrine carcinomas. What is ZL-1310? ZL-1310 is a novel antibody-drug conjugate (ADC) designed to target a protein called DLL3, which is commonly found on the surface of many neuroendocrine cancers. DLL3 is considered a new and promising treatment target, especially in GEP NECs. ADCs work by combining: an antibody, which seeks out cancer cells with a specific marker (like DLL3), and a drug payload, often a chemotherapy molecule, that is delivered directly to those cells. About This Study (NCT06885281) This trial is now enrolling patients to evaluate: Safety and side effects of ZL-1310 How well the drug works in DLL3-positive neuroendocrine carcinomas How the drug behaves in the body Optimal dose levels for future studies Who Can Join (Key Inclusion Criteria) This study includes two main groups of patients: Cohort 1: People with advanced GEP NECs (including cancers of the esophagus, stomach, pancreas, gallbladder/hepatobiliary system, or colon/rectum) Must have received 1–2 prior chemotherapy or other treatment regimens Cohort 2: People with other advanced NECs or solid tumors that express DLL3 Must have received 1–2 prior treatment regimens Additional notes for patients: DLL3 testing is not required before enrolling for GEP NECs or other NECs Previous treatment with other DLL3-targeted therapies is allowed For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: ZaiLab_1310-002_StudyTeam EMAIL: Zailab_1310-002_StudyTeam@zailaboratory.com PHONE: 86 021-61632588 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs << Back ACTION-1 ALPHA PRRT - Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT05477576 DRUG/TREATMENT: ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection COMPARED TO: Everolimus, Sunitinib, Octreotide, Lanreotide PHASE: Phase 3 STATUS: Recruiting April 2023 SPONSOR: RayzeBio, Inc. https://www.youtube.com/watch?v=U_cjeFdRZwk Dr. Heloisa Soares discusses the ACTION-1 Trial https://www.youtube.com/watch?v=w9kA8_gmVfM Dr. Will Pegna discusses the ACTION-1 Trial Starting at 5:07 DESCRIPTION: RayzeBio is sponsoring the ACTION-1 study, a phase 3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. Update - Aug 22, 2023 2023 ESMO Abstract shows preliminary safety and efficacy (Note: The meaning of efficacy in clinical trials refers to the capacity of a treatment, device, or medication, to produce a desired effect on the patient population.) Download the PDF here: 1198P-RYZ101-301-ESMO-2023-poster-UPLOAD .pdf Download PDF • 4.57MB For more information on eligibility criteria, trial locations, study details, etc ., go to ClinicalTrials.gov to view this trial here. OTHER HELPFUL RESOURCES: 'Alpha Radioligand Therapy in Neuroendocrine Neoplasms: Current Landscape and Spotlight on RYZ101' CONTACT: RayzeBio Clinical Trials EMAIL: clinicaltrials@rayzebio.com PHONE: 619-657-0057

<< Back PRRT/Radioligand Therapy (RLT) PRRT/RLT Trials 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC COMPOSE (GEP-NETs) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET Alpha PRRT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Combo Trial with Lu177 + Additional Medication Lu177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine in GEP-NETs Lu177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs PRRT for Specific Populations Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients PRRT Comparison Trial of Lu177 versus Another Medication COMPOSE (GEP-NETs) ComPareNET Lu-177 vs CAPTEM in PNETs DLL3-Targeted RLT 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

< Back to the upcoming events page ABOUT Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. Download Presentation Slides >>> ABOUT MEGHAN LASZLO, MS, RD, CSO Registered Dietitian Board-Certified Specialist in Oncology Nutrition Meghan Laszlo MS, RD, CSO is an oncology dietitian at Cedars-Sinai in Los Angeles, California. For individuals outside of Cedars-Sinai, Meghan Laszlo sees patients through Nourish, a telehealth platform that accepts insurance (Aetna, BCBS, Cigna, United). Insurance for telehealth is available to those residing in Arizona, California, Colorado, Connecticut, Hawaii, Idaho, Indiana, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming! Meghan Laszlo MS, RD, CSO Phone: 424-235-5026 RESOURCES T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

< Back to the upcoming events page https://www.youtube.com/watch?v=DcewKhYm8uY Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis, at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. ABOUT DR. ALLEN LUIS Dr. S. Allen Luis, MD, Ph.D, is the Associate Dean for Student and Faculty Affairs at the Mayo Clinic School of Health Sciences and the Associate Chair for Education for the Department of Cardiovascular Diseases. He also serves as Medical Director for the Mayo Clinic School of Health Sciences Echocardiography and Advanced Cardiovascular Sonography Programs. He works in the Carcinoid Heart Disease Clinic, is Co-director of the Pericardial Diseases Clinic and is an Associate Professor of Medicine at Mayo Clinic (Rochester, Minnesota). Dr. Luis is an Associate Editor for Frontiers in Cardiovascular Medicine and a member of the American Journal of Cardiology Editorial Board. He serves on the Board of Directors for the American College of Cardiology (Minnesota Chapter) and the Committee on Accreditation for Advanced Cardiovascular Sonography. Dr. Luis’ principal clinical and research interests include the use of echocardiography and multimodality cardiac imaging in the investigation, management and prognostication of patients with carcinoid heart disease. His other clinical and research interests include cardio-oncology, valvular heart disease and pericardial diseases. THANKS TO OUR SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

< Back to the upcoming events page https://www.youtube.com/watch?v=Vb7aH06UWrE Download PowerPoint Slides >>> Some Topics Covered: Types of Functional Neuroendocrine Tumors, Hormone-producing, Carcinoid Syndrome, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Diarrhea, Flushing, Hypoglycemia, Carcinoid Heart Disease, Cushing Syndrome, Somatostatinoma. ABOUT Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. THANKS TO OUR SPONSORS PRESENTING SPONSOR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs << Back Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu-177 Dotatate in Patients with Advanced Pancreatic Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT05247905 DRUG/TREATMENT: Lutetium Lu-177 Dotatate PRRT (Peptide Receptor Radionuclide Therapy) versus CAPTEM (Capecitabine and Temozolomide) PHASE: 2 STATUS: Closed SPONSOR: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) https://www.youtube.com/watch?v=jEO6in8giTk Dr. Heloisa Soares Discusses ComPareNET: Lu-177 DOTATATE vs CAPTEM DESCRIPTION: This phase II trial compares capecitabine and temozolomide to lutetium Lu-177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out whether capecitabine and temozolomide or lutetium Lu-177 dotatate may kill more tumor cells in patients with advanced pancreatic neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

IDE849 (DLL3-targeted ADC) ± Durvalumab in DLL3+ Tumors << Back A Study of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer IDENTIFIER ( ClinicalTrials.gov ) : NCT07174583 DRUG/TREATMENT : IDE849, an anti-DLL3 antibody-drug conjugate PHASE : 1/2 STATUS : Recruiting SPONSOR : IDEAYA Biosciences DESCRIPTION: This is a Phase 1/2, multi-center clinical trial studying a new treatment called IDE849 in people with DLL3-expressing cancers, including small cell lung cancer (SCLC), high-grade neuroendocrine carcinomas (NECs), and other solid tumors. What is DLL3? DLL3 (delta-like ligand 3) is a protein found on the surface of some cancer cells, especially high-grade neuroendocrine cancers. Because DLL3 is much less common on normal cells, it has become an important target for new cancer treatments. What is IDE849? IDE849 is an antibody-drug conjugate (ADC), a newer type of targeted cancer therapy. ADCs combine: an antibody, which acts like a homing device to find cancer cells with a specific marker (like DLL3), and a drug payload (often a chemotherapy-like agent) that is delivered directly to those cells IDE849 is designed to find DLL3-positive cancer cells and deliver a cancer-fighting drug directly to them, which may help kill cancer cells while limiting damage to healthy tissue. In this study, IDE849 is being tested: on its own, and in combination with other treatments, including durvalumab (an immunotherapy) or another investigational drug (IDE161) About the Study Researchers want to understand: Safety and side effects How well the treatment works How the drug moves through and affects the body (pharmacokinetics and immunogenicity) The best dose to use in future studies How the Study is Structured Part 1 (Dose Escalation): Participants receive increasing doses of IDE849 (alone or in combination) The goal is to find the safest and most effective dose Part 2 (Dose Expansion): Participants receive the selected dose(s) Researchers further evaluate safety and early effectiveness in specific groups of patients Who This Study Is For This study is enrolling people with: Small cell lung cancer (SCLC) High-grade neuroendocrine carcinomas (NECs) Other solid tumors that express DLL3 Why This Matters Treatment options for high-grade neuroendocrine carcinomas (NECs) and small cell lung cancer (SCLC) are often limited, especially after standard therapies stop working. DLL3-targeted therapies like IDE849 represent a promising new approach because they are designed to specifically target cancer cells that carry the DLL3 marker. By delivering treatment directly to these cells, this strategy may improve effectiveness while limiting damage to healthy tissue. This study is also exploring combination approaches, including immunotherapy, which may further enhance how well treatment works. If successful, this research could help expand treatment options for patients with DLL3-positive cancers, including those beyond small cell lung cancer. CONTACT For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. Name: IDEAYA Clinical Trials Phone Number: +1-855-433-2246 Email: IDEAYAClinicalTrials@ideayabio.com This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Back Carcinoid Syndrome CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine in Carcinoid Syndrome